

APPENDIX 16: INTERVENTIONS FOR ACUTE DEPRESSION – STUDY CHARACTERISTICS

1.1	Pharmacological interventions.....	2
1.2	Nutritional interventions	7
1.3	Physical interventions.....	7

Abbreviations

AUS	Australia
BPI	bipolar I disorder
CHN	China
Dur	duration
ESP	Spain
FRA	France
Freq	frequency
GBR	Great Britain
GER	Germany
IND	India
JPN	Japan
KOR	Korea
N	number of participants
N/A	not applicable
N Post	number of participants at post-treatment
NR	not reported
N Rand	number of participants randomised
NLD	Netherlands
POL	Poland
ROU	Romania
RUS	Russia
RSA	Republic of South Africa
TAU	treatment as usual
TMS	transcranial magnetic stimulation
TWN	Taiwan
UKR	Ukraine
USA	United States of America
XR	extended release

1.1 PHARMACOLOGICAL INTERVENTIONS

Study	Country	Age	% Female	% BPI	Concomitant medication	N Rand	N Post	Group	Dose	Freq	Dur
<i>Aripiprazole compared with placebo</i>											
BRISTOLMYERSSQUIB2006	USA	39	63%	100%	None	186	162	Aripiprazole	10 mg	14	8
						188	177	Placebo	N/A	14	8
BRISTOLMYERSSQUIB2007	USA	40	60%	100%	None	187	175	Aripiprazole	10 mg	14	8
						188	176	Placebo	N/A	14	8
QUANTE2010	GER	51	48%	74%	Citalopram with lithium or valproate	12	8	Aripiprazole	15 mg	7	6
						11	10	Placebo	N/A	7	6
<i>Bupropion, sertraline and venlafaxine</i>											
POST2006	USA, NLD, GER	42	50%	73%	Mood stabiliser and/or an antipsychotic	51	51	Bupropion	280 mg	7	10
						58	58	Setraline	190 mg	7	10
						65	65	Venlafaxine	195 mg	7	10
<i>Imipramine compared with moclobemide</i>											
SILVERSTONE2001	USA	37	100%	0%	Mood stabilisers, single benzodiazepine hypnotic	75	75	Imipramine	150 mg	7	8
						81	81	Moclobemide	600 mg	7	8
<i>Lamotrigine compared with placebo</i>											
CALABRESE1999	USA, GBR, FRA, AUS	41	60%	100%	None	66	64	Lamotrigine	50 mg	14	7
						63	63	Lamotrigine	200 mg	14	7
						66	65	Placebo	Placebo	14	7
CALABRESE2005	USA, GBR, FRA, AUS	41	60%	100%	Benzodiazepines (limited use)	181	NR	Quetiapine	300 mg	7	8
						180	NR	Quetiapine	600 mg	7	8
						181	NR	Placebo	N/A	7	8
CALABRESE2008a	USA	41	62%	NR	NR	103	102	Lamotrigine	200 mg	7	10

Interventions for acute depression – study characteristics

Study	Country	Age	% Female	% BPI	Concomitant medication	N Rand	N Post	Group	Dose	Freq	Dur
						103	100	Placebo	N/A	7	10
CALABRESE2008b	USA	37	55%	100%	NR	133	126	Lamotrigine	200 mg	7	8
						124	117	Placebo	N/A	7	8
CALABRESE2008c	USA	37	64%	0%	NR	111	109	Lamotrigine	200 mg	7	8
						110	105	Placebo	N/A	7	8
CALABRESE2008d	USA	38	54%	100%	NR	131	123	Lamotrigine	200 mg	7	8
						128	120	Placebo	N/A	7	8
VANDERLOOS2009	NLD, ESP	46	54%	68%	Lithium	64	64	Lamotrigine	200 mg	7	8
						60	60	Placebo	N/A	7	8
<i>Lamotrigine, gabapentin and placebo</i>											
FRYE2000	USA	NR	58%	35%	Levothyroxine, triiodothyronine and clonazepam allowed in phase I	NR	NR	Lamotrigine	300 mg	7	6
						NR	NR	Gabapentin	3,980 mg	7	6
						NR	NR	Placebo	N/A	7	6
<i>Lurasidone compared with placebo</i>											
SUNOVION2012a	GER, IND, POL, ROU, RUS, RSA, UKR, USA	42	48%	100%	Lithium or valproate allowed	183	179	Lurasidone	65 mg	7	6
						165	161	Placebo	N/A	7	6
SUNOVION2012b	USA, GBR, FRA, AUS	41	60%	100%	Lithium or valproate allowed	166	161	Lurasidone	32 mg	7	6
						169	162	Lurasidone	80 mg	7	6

Interventions for acute depression – study characteristics

Study	Country	Age	% Female	% BPI	Concomitant medication	N Rand	N Post	Group	Dose	Freq	Dur
						170	162	Placebo	N/A	7	6
<i>Olanzapine compared with placebo</i>											
TOHEN2012	JPN, CHN, TWN, KOR, USA	36	58%	100%	NR	343	343	Olanzapine	10 mg	7	6
						171	171	Placebo	N/A	7	6
<i>Olanzapine and fluoxetine combination compared with lamotrigine</i>											
BROWN2006	USA	37	60%	100%	Anticholinergics, benzodiazepines or other hypnotics allowed	205	202	Olanzapine and fluoxetine	10.7 mg/40.8 mg	7	7
						205	191	Lamotrigine	106.4 mg	7	7
<i>Olanzapine and fluoxetine combination, olanzapine and placebo</i>											
TOHEN2003	USA	37	57%	67%	Lorazepam and anticholinergic therapy	86	82	Olanzapine and fluoxetine	7.4 mg/39.3 mg	7	8
						370	351	Olanzapine	9.7 mg	7	8
						377	355	Placebo	N/A	7	8
<i>Paroxetine, imipramine and placebo</i>											
NEMEROFF2001	USA	36	NR	70%	Lithium, valproate and/or carbamazepine	35	33	Paroxetine	32.6 mg	7	10
						39	36	Imipramine	166.7 mg	7	10
						43	43	Placebo	N/A	7	10
<i>Quetiapine compared with placebo</i>											
SUPPES2010	USA	39	65%	80%	Lorazepam, zolpidem	140	133	Quetiapine XR	300 mg	7	8

Interventions for acute depression – study characteristics

Study	Country	Age	% Female	% BPI	Concomitant medication	N Rand	N Post	Group	Dose	Freq	Dur
					tartrate, zaleplon, zopiclone, chloral hydrate and anticholinergics allowed	130	137	Placebo	N/A	7	8
THASE2006	USA	37	57%	67%	Lorazepam and zolpidem tartrate allowed	172	155	Quetiapine	300 mg	7	8
						169	151	Quetiapine	600 mg	7	8
						168	161	Placebo	N/A	7	8
<i>Quetiapine compared with paroxetine</i>											
MCELROY2010	Multiple (not specified)	42	59%	62%	Lorazepam, zolpidem tartrate and chloral hydrate allowed	245	229	Quetiapine	300 mg	7	8
						247	232	Quetiapine	600 mg	7	8
						122	118	Paroxetine	20 mg	7	8
						126	121	Placebo	N/A	7	8
<i>Quetiapine, lithium and placebo</i>											
YOUNG2010	Multiple (not specified)	42	59%	62%	Lorazepam, zolpidem tartrate, zaleplon, zopiclone and chloral hydrate allowed	265	255	Quetiapine	300 mg	7	8
						268	263	Quetiapine	600 mg	7	8
						136	136	Lithium	490.5 mg	7	8
						133	129	Placebo	N/A	7	8
<i>Valproate compared with placebo</i>											
DAVIS2005	USA	41	11%	100%	Bedtime sedatives allowed	13	13	Valproate	1,250 mg	7	8
						12	12	Placebo	N/A	7	8

Interventions for acute depression – study characteristics

Study	Country	Age	% Female	% BPI	Concomitant medication	N Rand	N Post	Group	Dose	Freq	Dur
GHAEMI2007	USA	37	50%	50%	None	10	9	Valproate	1,028.8 mg	7	6
						8	9	Placebo	N/A	7	6
MUZINA2011	USA	39	57%	37%	Lorazepam and zolpidem allowed	26	26	Valproate	1,606 mg	7	6
						28	28	Placebo	N/A	7	6
<i>Ziprasidone compared with placebo</i>											
PAKAR2012	USA	39	53%	40%	Treatment as usual	NR	NR	Ziprasidone	80–160 mg	7	6
						NR	NR	Placebo	N/A	7	6
PFIZER2009a	USA	20	57%	100%	None	185	NR	Ziprasidone	40 mg	14	6
						196	NR	Placebo	N/A	14	6
PFIZER2009b	USA, GBR, FRA, AUS	41	60%	100%	None	171	NR	Ziprasidone	20 mg	14	6
						165	NR	Ziprasidone	40 mg	14	6
						168	NR	Placebo	N/A	14	6
SACHS2011	AUS, IND, USA	40	61%	100%	Lamotrigine, lithium or valproate; lorazepam allowed	148	147	Ziprasidone	40 mg	14	6
						150	147	Placebo	N/A	14	6

1.2 NUTRITIONAL INTERVENTIONS

Nutritional interventions											
<i>Omega-3 fatty acids compared with placebo</i>											
KECK2006B	NR	45	48%	74%	Mood stabilisers	59	NR	Eicosapentaenoic acid	6,000 mg	7	17
						57	NR	Placebo	N/A	7	17

1.3 PHYSICAL INTERVENTIONS

Physical interventions											
<i>Acupuncture compared with sham acupuncture</i>											
DENNEHY2009B	USA	41	69%	38%	Medication as usual	13	NR	Acupuncture	N/A	1.5	8
						13	NR	Sham	N/A	1.5	8
<i>Bright light therapy compared with low-density and high density air ionization</i>											
DAUPHINAIS2012	USA	43	74%	NR	Medication as usual	18	10	Bright light therapy	N/A	7	8
						20	11	Low-density negative air ionization	N/A	7	8
						6	2	High-density negative air ionization	N/A	7	8

Interventions for acute depression – study characteristics

<i>Chronotherapeutic augmentation treatment compared with treatment as usual (TAU)</i>											
WU2009	USA	39	41%	NR	Lithium and antidepressants	32	32	Sleep deprivation, bright light therapy and sleep phase advance	N/A	1	7
						17	17	TAU	N/A	1	7
<i>Transcranial magnetic stimulation (TMS) compared with sham TMS</i>											
NAHAS2003	USA	43	61%	61%	Carbamazepine, valproate or combination	11	11	TMS	20 minutes	7	2
						12	12	Sham TMS	20 minutes	7	2